Bioventus (NasdaqGS:BVS) FY Conference September 10, 2025 01:05 PM ET Company ParticipantsMark Singleton - CFO[Analyst]Thanks, everyone, for joining us. Before we begin, just a disclaimer. For important disclosures, please see the Morgan Stanley Research Disclosure website at morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. Thank you, everyone, for joining us. We're here with Mark Singleton, CFO of Bioventus. Thanks for being wit ...

CytomX Therapeutics (NasdaqGS:CTMX) FY Conference September 10, 2025 01:05 PM ET Company ParticipantsRoss Cohen - Executive Director in Health Care Investment BankingSean A. McCarthy - CEORoss CohenHey, everybody. Really quickly on disclosures, for important disclosures, please see the Morgan Stanley Research disclosure website. If you have any questions, please reach out to a Morgan Stanley sales representative. Thank you all for joining. Welcome to the Morgan Stanley Health Care Conference. I'm delighted ...

Disc Medicine (NasdaqGM:IRON) FY Conference September 10, 2025 01:05 PM ET Company ParticipantsJohn Quisel - CEO[Analyst]If you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have Disc Medicine with CEO John Quisel. Good afternoon and thanks for attending, John. I thought we'd commence by inviting you to make some comments, provide a bit of an overview of Disc and some catalysts coming up.John QuiselSounds good. Yeah, it's great to be here. Yeah, so Di ...

Arcellx (NasdaqGS:ACLX) FY Conference September 10, 2025 01:05 PM ET Company ParticipantsRami Elghandour - CEOChristopher Heery - CMOMichelle Gilson - CFOConference Call ParticipantsJudah Frommer - AnalystJudah FrommerGood afternoon, everyone. Welcome to this session of the Morgan Stanley Global Healthcare Conference. I'm excited to welcome the Arcellx team to the stage. Let me just read a quick disclosure before we get into it. For important disclosures, please see the Morgan Stanley Research Disclosure we ...

Parker-Hannifin (NYSE:PH) FY Conference September 10, 2025 01:00 PM ET Company ParticipantsJennifer Parmentier - Chairman & CEOConference Call ParticipantsNone - AnalystNoneAll right. Thank you, everybody. I'm super excited to be up here at Parker-Hannifin. We have CEO and Chair, Jennifer Parmentier. Jennifer, thank you so much for joining us today.Jennifer ParmentierThank you for having me.NoneAbsolutely. You know, Parker-Hannifin has really differentiated itself over the last five years, like incredible m ...

NovaGold Resources (NYSEAM:NG) 2025 Conference September 10, 2025 01:00 PM ET Company ParticipantsGregory Lang - President and CEOGregory LangThank you, Mike, and good morning, everyone. Thank you for taking a few minutes to get an update on NOVAGOLD. As I'm sure everybody understands, our presentation does include some forward looking materials. NovaGold went through a really significant transaction a couple months ago, and I'm gonna share the details with you in our presentation this morning. Yeah.Probabl ...

Brookfield Asset Management (NYSE:BAM) 2025 Investor Day September 10, 2025 01:00 PM ET Company ParticipantsJason Fooks - Managing Director and Head of Public Investor RelationsSikander Rashid - Global Head of AI InfrastructureHadley Peer Marshall - CFOBrian Kingston - Executive Chair, Real EstateChloe Berry - Portfolio Manager and Head of Infrastructure Income StrategyStephanie Ma - Company RepresentativeConnor Teskey - PresidentBart Dziarski - Company RepresentativeCherilyn Radbourne - Company Representat ...

BioHarvest Sciences (NasdaqGM:BHST) Update / Briefing September 10, 2025 01:00 PM ET Company ParticipantsIlan Sobel - CEOZaki Rakib - Chairman and President of CDMOConference Call ParticipantsNick Sherwood - AnalystRobert LeBoyer - AnalystHunter Diamond - AnalystMatt Hewitt - AnalystAlec Legg - AnalystOperatorGood day and welcome to the BioHarvest Sciences Virtual Investor Webinar. Today's webinar is being recorded. Before we begin the formal presentation, I'd like to remind everyone that statements made on ...

SERENITY At-Home Trial Overview - The SERENITY At-Home trial evaluated the safety and tolerability of BXCL501 (120 mcg) for agitation associated with bipolar disorder or schizophrenia in the at-home setting[2, 27, 28] - The trial design was a double-blind, placebo-controlled study with a 1:1 randomization to BXCL501 (N=100) or placebo (N=100) over a 12-week period[27] - The study included patients aged 18-75 years with bipolar I or II disorder, schizophrenia, schizoaffective, or schizophreniform disorder on a stable psychotropic regimen[30] Key Results - The trial collected data from 2,628 agitation episodes in 215 patients, with 2,437 episodes treated in 208 patients[21, 22, 36] - 168 (81%) of treated patients completed the full 12-week study, with an average of 117 agitation episodes recorded per treated patient[36] - No drug-related serious adverse events (SAEs), falls, or syncopes were reported in the BXCL501 arm[23, 37] - The adverse event profile was consistent with the approved IGALMI® label and other clinical trials in institutional settings[23, 37] - Somnolence was the most common treatment-emergent adverse event (TEAE) in the BXCL501 group, occurring in 23 (225%) of patients after the first dose and 161 (139%) of all doses[38] Clinical Benefit - BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (P<005)[41] - Complete resolution of agitation was significantly higher with BXCL501 compared to placebo across agitation episode severity (P<0001)[41] - For fully resolved episodes by baseline severity, BXCL501 showed higher percentages than placebo across mild, moderate, and severe agitation episodes[43] Next Steps - BioXcel Therapeutics plans to prepare and submit an sNDA (supplemental New Drug Application) in Q1 2026 for label expansion of IGALMI®[12, 23]

Inotiv (NasdaqCM:NOTV) FY Conference September 10, 2025 01:00 PM ET Speaker0Alright. Well, good afternoon, everyone, and welcome to our next session. Again, welcome, and thank you for joining the H. C. Wainwright twenty seventh Annual Global Investment Conference.My name is Matt Keller. I'm a vice president in the equity research department, and it is my pleasure to introduce our next company and our next presenter. With us, we have Robert Leisure, the CEO of Inotiv. Robert, the floor is all yours.Speaker1T ...